What did @nutritionbee actually say?
Honestly, it's hard to know. The transcript from this video is largely incoherent, likely the result of auto-generated captions struggling with unclear audio. What we can piece together: the creator is discussing MK-677, referencing something about FDA approval, mentioning side effects including "drying of the skin" and something described as "milk and milk" (possibly gynecomastia or fluid retention), and making vague claims about the compound's effects on muscles and the body. The phrase "animal use" also appears, which is actually relevant, as we'll get to. The creator frames this as being "for knowledge purpose only," which is a common disclaimer that doesn't actually limit the influence the content has on viewers.
Given the 16,200 views, even a garbled message about an unscheduled but investigational compound can drive purchasing decisions. That's worth taking seriously, regardless of how unclear the delivery was.
Does the science back this up?
MK-677, also known as ibutamoren, is a ghrelin receptor agonist that stimulates growth hormone secretion. It is not FDA-approved for human use. Period. Whatever the creator meant by "the FDA approved the bill," this is factually wrong and potentially dangerous misinformation.
Here's what the research actually shows. MK-677 does increase growth hormone and IGF-1 levels in humans. A randomized controlled trial by Nass et al. (2008, Annals of Internal Medicine) found that MK-677 increased lean body mass and improved GH secretion in healthy older adults over 12 months. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) demonstrated significant increases in lean mass in obese men. So there's real pharmacological activity here. The compound does something. But "does something" and "is safe and approved" are very different claims.
Documented side effects in clinical trials include edema, muscle pain, increased appetite, and elevated fasting glucose. The skin-drying claim is not well-supported in the literature and appears to be anecdotal or confused with other compounds.
What did they get wrong (or right)?
Wrong, and significantly: the FDA approval claim. MK-677 has never been approved by the FDA for any human indication. It has been studied under investigational new drug applications, but development was largely discontinued after Merck's trials showed mixed results in hip fracture patients (Adunsky et al., 2011, Archives of Gerontology and Geriatrics). Telling an audience of over 16,000 people that a compound is FDA-approved when it is not is not a minor error.
Partially right: the side effect mention. The creator gestures at side effects existing, which is more than many MK-677 promoters do. Acknowledging that the compound has downsides is accurate, even if the specific "drying of the skin" claim doesn't match clinical trial data well.
Also worth flagging: the reference to "animal use" is actually the most accurate thing in this transcript. MK-677 is legally sold in the U.S. as a research chemical, not for human consumption. Many suppliers list it explicitly for laboratory or animal research purposes only. If that's what the creator was referencing, credit where it's due.
What should you actually know?
MK-677 occupies a gray zone that makes it genuinely confusing for consumers. It is not a controlled substance under the Controlled Substances Act, so it's not illegal to possess in most U.S. states. But it is also not approved for human use, meaning no product sold as MK-677 for consumption has undergone the safety and efficacy review required for pharmaceuticals. That gap matters.
If you're seeing this compound promoted on telehealth platforms, ask specific questions: Is this compounded by an FDA-registered pharmacy? What is the prescribing indication? What monitoring is included? Legitimate clinical use, if a provider decides it's appropriate, should come with baseline labs, follow-up IGF-1 monitoring, and a clear conversation about the limited long-term human safety data.
The insulin resistance signal from trials is real and underreported in social media content. Anyone with prediabetes or metabolic concerns should be especially cautious. And stacking MK-677 with other GH-axis compounds without clinical supervision is the kind of thing that ends up as a case report in a journal, not in a before-and-after photo.
Bottom line on this video
This content is too incoherent to be meaningfully harmful in a specific way, but that doesn't make it harmless. Vague enthusiasm about an unapproved compound, a false FDA approval claim, and 16,000 viewers is a combination that warrants scrutiny. The disclaimer "for knowledge purpose only" does not substitute for accurate information. If you're curious about MK-677, the peer-reviewed literature is publicly accessible. Start there, not here.